GSK3B and hepatocellular carcinoma: In HCC and NSCLC cells, AS-IV [50,68] suppresses the formation of EMTs by specifically targeting the Akt/GSK-3β/β-catenin signaling pathway, increasing the expression of E-cadherin and decreasing the expression of N-cadherin.